Techne (TECH) reported $286.56 million in revenue for the quarter ended September 2025, representing a year-over-year decline of 1%. EPS of $0.42 for the same period compares to $0.42 a year ago.
The reported revenue represents a surprise of -0.96% over the Zacks Consensus Estimate of $289.34 million. With the consensus EPS estimate being $0.42, the company has not delivered EPS surprise.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Techne performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic Growth: -1% versus 1.1% estimated by two analysts on average.
- Net Sales- Protein Sciences: $202.2 million versus the two-analyst average estimate of $208.25 million. The reported number represents a year-over-year change of -1.1%.
- Net Sales- Diagnostics and Spatial Biology: $79.5 million compared to the $80.65 million average estimate based on two analysts. The reported number represents a change of -4.4% year over year.
View all Key Company Metrics for Techne here>>>
Shares of Techne have returned +3.2% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bio-Techne Corp (TECH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
